Aaron Seth Rosenberg, MD, MS, discusses the emerging role of minimal residual disease to guide treatment decisions in multiple myeloma.
Aaron Seth Rosenberg, MD, MS
Advertisement
Articles by Aaron Seth Rosenberg, MD, MS
Aaron Seth Rosenberg, MD, MS, discusses the potential clinical implications of the phase 2 GRIFFIN trial in multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
3
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
4
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
5